Search

Displaying results 2241 - 2250 of 10000 in total
  1. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  2. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].

  3. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … prevents the first step in the HIV-1 viral lifecycle.

  4. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma … It is administered with [DB01042] via mild hyperthermic isolated limb perfusion.

  5. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    produced in Chinese Hamster Ovary (CHO) culture. … [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity

  6. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

  7. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Chlordiazepoxide

    go.drugbank.com/drugs/DB00475
    ApprovedIllicit

    An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

  9. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. … Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine.

  10. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.